HC Wainwright Reaffirms Buy Rating for Krystal Biotech (NASDAQ:KRYS)

Key Points

• HC Wainwright has reaffirmed a buy rating for Krystal Biotech (KRYS) with a target price of $240.00, indicating a potential upside of 64.72% from its current price.
• Despite adjustments from other analysts, Krystal Biotech has a consensus rating of Buy from analysts, with an average price target of $210.75.
• The company reported earnings per share (EPS) of $1.29 for the last quarter, surpassing expectations and highlighting a strong net margin of 40.85%.

HC Wainwright reaffirmed their buy rating on shares of Krystal Biotech (NASDAQ:KRYS - Free Report) in a report issued on Friday,Benzinga reports. They currently have a $240.00 price target on the stock.

KRYS has been the subject of a number of other reports. Chardan Capital restated a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research report on Tuesday, August 5th. Citigroup restated a "neutral" rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. Bank of America cut their target price on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Finally, Guggenheim cut their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $210.38.

Krystal Biotech Stock Up 3.3%

KRYS stock traded up $4.79 during trading on Friday, reaching $150.49. 246,954 shares of the company's stock were exchanged, compared to its average volume of 425,092. Krystal Biotech has a 1-year low of $122.80 and a 1-year high of $207.84. The company's fifty day moving average price is $144.22 and its 200-day moving average price is $154.50. The firm has a market cap of $4.36 billion, a PE ratio of 30.59 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The company had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. As a group, sell-side analysts expect that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the company's stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the sale, the insider directly owned 1,508,056 shares of the company's stock, valued at approximately $226,208,400. This represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 49,800 shares of company stock worth $7,487,943 over the last ninety days. 13.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds have recently bought and sold shares of the business. State Street Corp lifted its stake in Krystal Biotech by 10.5% in the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company's stock worth $186,306,000 after acquiring an additional 128,639 shares in the last quarter. Soleus Capital Management L.P. raised its holdings in shares of Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company's stock worth $126,870,000 after acquiring an additional 481,200 shares in the last quarter. Braidwell LP raised its holdings in shares of Krystal Biotech by 81.6% during the second quarter. Braidwell LP now owns 727,811 shares of the company's stock worth $100,045,000 after acquiring an additional 327,067 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Krystal Biotech by 1.2% during the second quarter. Geode Capital Management LLC now owns 619,547 shares of the company's stock worth $85,174,000 after acquiring an additional 7,194 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock worth $103,764,000 after acquiring an additional 365,304 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).